Basiliximab: Clinical Trials

25 trials of Basiliximab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 2 unknown, 1 recruiting, 1 terminated. 25 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 325Completed 20, Unknown 2, Recruiting 1, Terminated 1, Withdrawn 1
Phase 23Completed 1, Terminated 1, Withdrawn 1

Follow Basiliximab: new trials by email Literature Review of Basiliximab trials Research Report on Basiliximab

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
Rabbit Anti thymocyte globulin (rATG), Basiliximab - Renal Transplant Rejection, Induction Therapy
Phase 3RecruitingUniversity Hospital, Tours2442023-11-072026-06-18
Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT
UC-MSC, Anti-CD25 mAb - Graft Vs Host Disease
Phase 3CompletedPeking University People's Hospital1302021-02-012023-06-01
12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients
Everolimus, Tacrolimus, Cyclosporin A - Kidney Transplantation, Renal Transplantation
Phase 3CompletedNovartis Pharmaceuticals6122012-12-272017-05-01
A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients
tacrolimus, everolimus, Basiliximab - Liver Transplantation
Phase 3CompletedNovartis Pharmaceuticals1882012-12-012016-04-27
Thymoglobulin Induction in Kidney Transplant Recipients
antithymocyte globulin, Basiliximab - Kidney Transplantation, Ischemia-Reperfusion Injury
Phase 3UnknownUniversity of Oxford402011-01-012010-11-11
Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
Alemtuzumab, Basiliximab, Sirolimus - Kidney Transplantation
Phase 2 / Phase 3CompletedUniversity of Oxford8522010-09-012020-04-02
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
Advagraf, Mycophenolate Mofetil, Basiliximab - Liver Transplantation
Phase 3CompletedAstellas Pharma Inc8932009-09-302024-11-01
Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Certican®, Neoral, Myfortic - Renal Interstitial Fibrosis
Phase 3CompletedNovartis Pharmaceuticals1942009-09-012014-03-18
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
tacrolimus, Simulect, Cellcept - Kidney Transplantation
Phase 3CompletedAstellas Pharma Inc2812009-08-172024-11-01
Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant
basiliximab - End Stage Renal Disease
Phase 2 / Phase 3TerminatedDrexel University College of Medicine52009-05-012015-02-10
CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment
anti-CD 25 mAb, Sirolimus, MMF - End Stage Liver Disease, Impaired Renal Function
Phase 3CompletedUniversity of Regensburg272008-12-012014-12-16
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Everolimus, Mycophenolate mofetil (MMF), Basiliximab - Kidney Transplantation
Phase 3CompletedNovartis1222008-02-012013-06-21
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
Islets of Langerhans transplantation - Type 1 Diabetes Mellitus
Phase 3CompletedCellTrans Inc.212007-09-052026-11-04
Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen
Everolimus, Myfortic, Sandimmun Optoral - Kidney Transplantation
Phase 3CompletedNovartis Pharmaceuticals8022007-07-012017-01-18
EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function
basiliximab - Kidney Transplant
Phase 3UnknownMcGill University Health Centre/Research Institute of the McGill University Health Centre502007-04-012007-04-12
Efficacy of Islet After Kidney Transplantation
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab - Type 1 Diabetes Mellitus
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)242007-01-012017-10-20
Islet Transplantation in Type 1 Diabetes
Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus - Type 1 Diabetes Mellitus
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)482006-10-012019-07-17
Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
everolimus, basiliximab, CNI - Liver Transplantation
Phase 3CompletedNovartis Pharmaceuticals2762006-08-012015-02-06
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA) - Kidney Transplantation, Graft Rejection
Phase 3CompletedNovartis8332005-10-012011-05-10
Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients
Everolimus (Certican), Cyclosporine (Neoral), Steroid - Organ Transplantation, Renal Transplantation
Phase 3CompletedNovartis1142005-07-012018-08-09

Showing 20 of 25. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 1 (3)  ·  Rejection, Psychology (3)  ·  Graft vs Host Disease (2)  ·  Hypoglycemia (2)  ·  Emphysema (1)  ·  End Stage Liver Disease (1)  ·  Hepatitis C (1)  ·  Infections (1)  ·  Kidney Failure, Chronic (1)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Renal Insufficiency (1)  ·  Reperfusion Injury (1)

Sponsors

Novartis (6)  ·  Novartis Pharmaceuticals (5)  ·  Astellas Pharma Inc (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  University of Oxford (2)  ·  CellTrans Inc. (1)  ·  Drexel University College of Medicine (1)  ·  Genentech, Inc. (1)  ·  McGill University Health Centre/Research Institute of the McGill University Health Centre (1)  ·  Peking University People's Hospital (1)  ·  University Health Network, Toronto (1)  ·  University Hospital, Tours (1)  ·  University of Regensburg (1)

Countries

Canada (6)  ·  Germany (6)  ·  France (5)  ·  United States (5)  ·  Switzerland (3)  ·  United Kingdom (3)  ·  Austria (2)  ·  Argentina (1)  ·  Belarus (1)  ·  Belgium (1)  ·  Brazil (1)  ·  China (1)  ·  Colombia (1)  ·  Czechia (1)  ·  Finland (1)

Top investigators

Ali Naji, PhD (1)  ·  Andreas A Schnitzbauer, MD (1)  ·  Andrew Posselt, MD, PhD (1)  ·  Bernhard Hering, MD (1)  ·  Camillo Ricordi, MD (1)  ·  Cecilia Chaparro, MD (1)  ·  Colin Baigent (1)  ·  Hans J Schlitt, MD (1)  ·  James F. Markmann, MD, PhD (1)  ·  James Shapiro, MD, PhD (1)  ·  Jose Oberholzer, MD (1)

Results publications

PMID 39382091, PMID 19005405, PMID 19005406, PMID 20840760, PMID 23230975, PMID 23422495, PMID 23438305, PMID 23630300, PMID 23641902, PMID 23866828, PMID 25078310, PMID 25629445, PMID 26018348, PMID 26888217, PMID 27208344, PMID 27465220, PMID 28605781, PMID 29226570, PMID 29563196, PMID 29779835, PMID 30231851, PMID 30582281, PMID 30903722, PMID 31530561, PMID 38413930, PMID 38993854, PMID 39082471, PMID 39735417, PMID 39739990

NIH funding

2008 (2), 2009 (2), 2005 (1)